Abstract:The nuclear factor-E2-related factor 2 (NRF2) serves as a master regulator in cellular defense against oxidative stress and chemical detoxification. However, persistent activation of NRF2 resulting from mutations in NRF2 and/or downregulation of or mutations in its suppressor, Kelch-like ECH-associated protein 1 (KEAP1), is associated with tumorigenicity and chemoresistance of non-small-cell lung carcinomas (NSCLCs). Thus, inhibiting the NRF2-mediated adaptive antioxidant response is widely considered a promising strategy to prevent tumor growth and reverse chemoresistance in NSCLCs. Unexpectedly, stable knockdown of KEAP1 by lentiviral shRNA sensitized three independent NSCLC cell lines (A549, HTB-178, and HTB-182) to multiple chemotherapeutic agents, including arsenic trioxide (As(2)O(3)), etoposide, and doxorubicin, despite moderately increased NRF2 levels. In lung adenocarcinoma epithelial A549 cells, silencing of KEAP1 augmented the expression of peroxisome proliferator-activated receptor γ (PPARγ) and genes associated with cell differentiation, including E-cadherin and gelsolin. In addition, KEAP1-knockdown A549 cells displayed attenuated expression of the proto-oncogene cyclin D1 and markers for cancer stem cells (CSCs) and reduced nonadherent sphere formation. Moreover, deficiency of KEAP1 led to elevated induction of PPARγ in response to As(2)O(3). Pretreatment of A549 cells with PPARγ agonists activated PPARγ and augmented the cytotoxicity of As(2)O(3). A mathematical model was formulated to advance a hypothesis that differential regulation of PPARγ and detoxification enzymes by KEAP1 and NRF2 may underpin the observed landscape changes in chemosensitivity. Collectively, suppression of KEAP1 expression in human NSCLC cells resulted in sensitization to chemotherapeutic agents, which may be attributed to activation of PPARγ and subsequent alterations in cell differentiation and CSC abundance.

NRF2 Regulates Serine Biosynthesis in Non-Small Cell Lung Cancer

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

NRF2 SUMOylation Promotes De Novo Serine Synthesis and Maintains HCC Tumorigenesis.

NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.

NRF2 has a splicing regulatory function involving the survival of motor neuron (SMN) in non-small cell lung cancer

“NRF2 Addiction” in Lung Cancer Cells and Its Impact on Cancer Therapy

Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer

5-methylcytosine transferase NSUN2 drives NRF2-mediated ferroptosis resistance in non-small cell lung cancer

SUMOylation of the Ubiquitin Ligase Component KEAP1 at K39 Upregulates NRF2 and Its Target Function in Lung Cancer Cell Proliferation.

NRF2 Activation Induces NADH-reductive Stress, Providing a Metabolic Vulnerability in Lung Cancer

Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma

Regulation of SIRT2 Levels for Human Non-Small Cell Lung Cancer Therapy.

Regulatory Role of KEAP1 and NRF2 in PPARγ Expression and Chemoresistance in Human Non-Small-cell Lung Carcinoma Cells.

Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer

Serine enrichment in tumors promotes regulatory T cell accumulation through sphinganine-mediated regulation of c-Fos

Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer

NRF2 Regulates Cystathionine Gamma-Lyase Expression and Activity in Primary Airway Epithelial Cells Infected with Respiratory Syncytial Virus

Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis

Distinct Roles for the Thioredoxin and Glutathione Antioxidant Systems in Nrf2-Mediated Lung Tumor Initiation and Progression

PPIA Dictates NRF2 Stability to Promote Lung Cancer Progression